Roivant Sciences is trading 7.18% up now at $38.80 after investors reacted favorably to its narrower first-quarter loss despite weaker revenue.
- August 6 results showed a $0.26-per-share loss versus a $0.30 estimate; revenue missed expectations.
- Management highlighted nearly $4 billion in cash and brepocitinib’s potential September launch.
- No new August 14–17 company announcement was identified, suggesting a delayed earnings-related reaction.